Xconomy | Boston - Business + Technology in the Exponential Economy

Zafgen, Developer of Fat-Shrinking Drugs, Hires Novartis Scientist as New CEO and Emerges From Stealth Mode
Zafgen’s Big Idea: Fight Fat by Cutting Off Its Blood Supply
Harvard Researcher to Helm Merck’s Cancer Research, Genzyme Acquires Certain Exact Sciences Assets, NeurAxon Out to Axe Migraines, & More Boston-Area Life Sciences
Exact Teams With Genzyme, Shrugs off Sequenom; Virtual Computer Reels in $15M; Beacon Power Inks National Grid Agreement; & More Boston-Area Deal News
How to Raise $50M in a Recession: Highlights from the Xconomy Life Sciences Forum

Zafgen Cuts Deal With Argenta

Zafgen, the Cambridge, MA-based developer of drugs to shrink fat tissue, said today it has formed a partnership with Harlow, UK-based Argenta Discovery. Argenta, a contract research firm, will assist with the development of one of Zafgen’s experimental treatments for obesity. Earlier this week, we profiled this company’s quest to pioneer a new method of treatment which cuts off blood flow to fat tissue. Financial terms of the new partnership weren’t disclosed.

Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.

Comments | Reprints | Share: